Lurasidone: Ten Years Treating Adults with Bipolar Depression
DOI:
https://doi.org/10.51338/rppsm.2021.v7.i2.199Keywords:
Adult, Antipsychotic Agents/therapeutic use, Bipolar Disorder/drug therapy, Lurasidone Hydrochloride/ therapeutic useAbstract
Lurasidone is an atypical antipsychotic approved in 2010 in Canada and in the USA for the treatment of adults with schizophrenia or bipolar type I disorder. In 2014 it was approved in the European Union for the treatment of patients with 13 years‑old or older, with schizophrenia. Lurasidone is a benzisothiazole derivative with a binding profile that makes it an antidepressant candidate with a low metabolic impact. In patients with bipolar disorder, depressive episodes tend to be present for the majority of the time and are difficult to treat, as shown in multiple surveys indicating that more than three quarters of patients with bipolar depression receive at least two pharmaceutical drugs and more than one third receive three or more. Some relevant international guidelines include different first‑line options in the treatment of bipolar depression, among which is lurasidone. Considering the difficulties in treating depressive episodes in bipolar disorder, the EU marketing authorization limiting the use of lurasidone in schizophrenia only and the expectable commercialization in Portugal by 2021, we aim to review the literature regarding the efficacy and advantages of lurasidone for depressive episodes of bipolar disorder and to discuss the usefulness of approving this medication as an alternative treatment approach.
Downloads
References
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5‑hydroxytryptamine 7 (5‑HT7) and 5‑HT1A receptor activity. J Pharmacol Exp Ther. 2010;334:171‑81. doi:10.1124/jpet.110.167346.
Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1‑histamine receptor affinity predicts short‑term
weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003; 28:519‑26. doi:10.1038/sj.npp.1300027
Reynolds GP, Hill MJ, Kirk SL. The 5‑HT2C receptor and antipsychotic induced weight gain ‑ mechanisms and genetics. J Psychopharmacol. 2006; 20:15‑8. doi:10.1177/1359786806066040.
Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5‑HT)(1A) receptors. J Pharmacol Exp Ther. 2000; 295:853‑61.
Hedlund PB, Huitron‑Resendiz S, Henriksen SJ, Sutcliffe JG. 5‑HT7 receptor inhibition and inactivation induce antidepressant‑like behavior and sleep pattern. Biol Psychiatry. 2005; 58:831‑7. doi:10.1016/j.biopsych.2005.05.012.
Carvalho AF, Firth J, Vieta E. Bipolar Disorder. N Engl J Med. 2020; 383:58‑66. doi: 10.1056/NEJMra1906193.
Tondo L, Vázquez GH, Baldessarini RJ. Options for pharmacological treatment of refractory bipolar depression. Curr Psychiatry Rep. 2014;16:431. doi:10.1007/s11920‑013‑0431‑y.
Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013; 27:515‑29. doi:10.1007/s40263‑013‑0073‑y.
Greil W, Häberle A, Haueis P, Grohmann R, Russman S. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord. 2012; 136:534‑42. doi:10.1016/j.jad.2011.10.033.
Latuda (lurasidone hydrochloride) [Internet]. 2020 [cited 2020 Dez 10]. Available from: https://www.sunovion.ca/monographs/latuda.pdf
FDA [Internet]. 2013 [cited 2020 Dez 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603lbls10s11.pdf
European Medicines Agency [Internet]. 2014 [cited 2020 Dez 10]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/latuda
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97‑170. doi:10.1111/bdi.12609
Evidence‑based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. Full guideline. 2016[cited2021mar5]. Available from: https://www.bap.org.uk/docdetails.php?docID=6
Malhi GS, Bassett Darryl, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49:1087‑206. doi:10.1177/0004867415617657.
National Institute for Health and Care Excellence. Clinical Guideline Number 185 (CG185); Bipolar disorder: assessment and management [cited 2021
mar 9]. Available from: https://www.nice.org.uk/guidance/cg185/resources/bipolar‑disorder‑assessment‑and‑management‑pdf‑35109814379461.
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11:81–109. doi:10.3109/15622970903555881
Pfennig A, Bschor T, Baghai T, Bräunig P, Brieger P, Falkai P, et al. S3‑Leitlinie zur Diagnostik und Therapie bipolarer Störungen: Entwicklungsprozess und wesentliche Empfehlungen. Nervenarzt. 2012; 83:568‑86. doi: 10.1007/s00115‑011‑3415‑3.
Hasler G, Preisig M, Müller T. Bipolare Störungen: update 2015. Schweizerisches Med Forum. 2015; 15:486–94.
Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013; 170:1249‑62. doi:10.1176/appi.ajp.2013.13020185.
Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence‑based guidelines for treating bipolar disorders: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016; 30:495‑553.
Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double‑blind, placebo‑controlled study. Am J Psychiatry. 2014; 171:160‑8. doi:10.1176/appi.ajp.2013.13070984
Chapel S, Chiu Y, Hsu J, Cucchiaro J, Loebel A. Lurasidone Dose Response in Bipolar Depression: A Population Dose‑response Analysis. Clin Ther. 2016;38:4‑15.
doi:10.1016/j.clinthera.2015.11.013.
Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, et al. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double‑Blind, Placebo‑Controlled Study. Am J Psychiatry. 2016;173:400‑7. doi:10.1176/appi.ajp.2015.15060770.
Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, et al. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double‑Blind, Placebo‑Controlled Studies. J Clin Psychiatry. 2016;77:e1324‑e1331. doi:10.4088/JCP.15m10261.
Nagpal K, Kumar M, Kumar R. Utility of lurasidone in bipolar disorder type IV patient‑A case report. Asian J Psychiatry. 2017;29:164‑5. doi:10.1016/j.ajp.2017.05.020.
Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double‑blind, placebo‑controlled study. Am J Psychiatry. 2013;171:169‑77. doi:10.1176/appi.ajp.2013.13070985.
Suppes T, Kroger A, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo‑controlled trial utilizing prospective
and retrospective enrolment cohorts. J Psychiatr Res. 2016;78:86‑93. doi:10.1016/j.jpsychires.2016.03.012.
Tohen M, Ng‑Mak D, Rajagopalan K, Halpern R, Chuang CC, Loebel A. Patient Characteristics Associated with Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States. Prim Care Companion CNS Disord. 2017;19. doi:10.4088/PCC.16m02066
Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple‑treatments meta‑analysis. Acta Psychiatr Scand. 2014; 130:452‑69. doi:10.1111/acps.12343.
Cifariello A, Pompili A, Gasbarri A. 5‑HT7 receptors in the modulation of cognitive processes. Behav Brain Res. 2008; 195: 171‑9. doi: 10.1016/j.bbr.2007.12.012.
Yatham LN, Mackala S, Basivireddy J, Ahn S, Walji N, Hu C, et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open‑label, pilot study. Lancet Psychiatry. 2017; 4:208‑17. doi:10.1016/S2215‑0366(17)30046‑9.
Rajagopalan K, Bacci ED, Ng‑Mak D, Wyrwich K, Pikalov A, Loebel A. Effects on health‑related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC Psychiatry. 2016;16:157. doi:10.1186/s12888‑016‑0865‑y.
Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A. Lurasidone in the long‑term treatment of patients with bipolar disorder: a 24‑week open‑label extension study. Depress Anxiety. 2016; 33:424‑34. doi:10.1002/da.22479.
Forester BP, Sajatovic M, Tsai J, Pikalov A, Cucchiaro J, Loebel A. Safety and Effectiveness of Long‑Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post‑Hoc Analysis of a 6‑Month, Open‑Label Study. Am J Geriatr Psychiatry. 2018; 26:150‑9. doi:10.1016/j.jagp.2017.08.013.
Calabrese JR, Pikalov A, Streicher C, Cucchiaro J, Mao Y, Loebel A. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol. 2017; 27:865‑76. doi:10.1016/j.euroneuro.2017.06.013.
Miller S, Do D, Gershon A, Wang PW, Hooshmand F, Chang LS, et al. Longer‑Term Effectiveness and Tolerability of Adjunctive Open Lurasidone in Patients With Bipolar Disorder. J Clin Psychopharmacol. 2018;38:207‑211. doi:10.1097/JCP.0000000000000867.
Schaffer CB, Schaffer LC, Nordhal TE, Stark NM, Gohring CE. An Open Trial of Lurasidone as an Acute and Maintenance Adjunctive Treatment for Outpatients
With Treatment‑Resistant Bipolar Disorder. J Clin Psychopharmacol. 2016; 36:88‑9. doi:10.1097/jcp.0000000000000450.
